These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 3164256
1. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Cancer Res; 1988 Jul 15; 48(14):4107-12. PubMed ID: 3164256 [Abstract] [Full Text] [Related]
2. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course. Barak V, Carlin D, Sulkes A, Treves A, Biran S. Isr J Med Sci; 1988 Jul 15; 24(9-10):623-7. PubMed ID: 3204010 [Abstract] [Full Text] [Related]
3. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. Fujino N, Haga Y, Sakamoto K, Egami H, Kimura M, Nishimura R, Akagi M. Jpn J Clin Oncol; 1986 Dec 15; 16(4):335-46. PubMed ID: 3467106 [Abstract] [Full Text] [Related]
4. Human tissue polypeptide antigen in breast cancer. Nemoto T, Constantine R, Chu TM. J Natl Cancer Inst; 1979 Dec 15; 63(6):1347-50. PubMed ID: 292806 [Abstract] [Full Text] [Related]
5. [Clinical evaluation of tumor markers in breast cancer patients]. Ito T, Tanaka S, Ban K, Sakai N, Oshita H, Oiwa T, Kanno A, Kashizuka T. Gan To Kagaku Ryoho; 1987 Oct 15; 14(10):2917-23. PubMed ID: 3310907 [Abstract] [Full Text] [Related]
6. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. Hayes DF, Zurawski VR, Kufe DW. J Clin Oncol; 1986 Oct 15; 4(10):1542-50. PubMed ID: 2428949 [Abstract] [Full Text] [Related]
7. [Evaluation of tumor marker CA15-3 in breast cancer]. Kikuchi K, Uematsu Y, Takada Y, Kurihara E, Suito T, Fujisaki M, Takahashi R, Tamura T. Gan To Kagaku Ryoho; 1987 Nov 15; 14(11):3095-100. PubMed ID: 3479052 [Abstract] [Full Text] [Related]
8. [Clinical usefulness of tumor markers in breast cancer]. Konishi K, Karaki K, Watanabe K, Tsuda H, Konishi F. Rinsho Byori; 1993 Oct 15; 41(10):1108-15. PubMed ID: 8254956 [Abstract] [Full Text] [Related]
10. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer. Murray A, Willsher P, Price MR, Dixon AR, Robertson JF. Anticancer Res; 1997 Oct 15; 17(3C):1945-9. PubMed ID: 9216649 [Abstract] [Full Text] [Related]
12. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H. Jpn J Clin Oncol; 2006 Mar 15; 36(3):150-3. PubMed ID: 16520359 [Abstract] [Full Text] [Related]
16. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. al-Jarallah MA, Behbehani AE, el-Nass SA, Temim L, Ebraheem AK, Ali MA, Szymendera JJ. Eur J Surg Oncol; 1993 Feb 15; 19(1):74-9. PubMed ID: 8436243 [Abstract] [Full Text] [Related]
20. Elevated serum carcinoembryonic antigen and prognosis of breast cancer patients postmastectomy. Paulick R, Caffier H. Cancer Detect Prev; 1988 Feb 15; 11(3-6):311-7. PubMed ID: 3390852 [Abstract] [Full Text] [Related] Page: [Next] [New Search]